Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Clinical trial NCT05171816 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05171816
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-24
- Primary completion
- 2024-01-22
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.